MX2015015638A - Metodos para diseñar celulas t altamente activas para inmunoterapia. - Google Patents

Metodos para diseñar celulas t altamente activas para inmunoterapia.

Info

Publication number
MX2015015638A
MX2015015638A MX2015015638A MX2015015638A MX2015015638A MX 2015015638 A MX2015015638 A MX 2015015638A MX 2015015638 A MX2015015638 A MX 2015015638A MX 2015015638 A MX2015015638 A MX 2015015638A MX 2015015638 A MX2015015638 A MX 2015015638A
Authority
MX
Mexico
Prior art keywords
cells
methods
immunotherapy
cell
highly active
Prior art date
Application number
MX2015015638A
Other languages
English (en)
Inventor
Galetto Roman
Gouble Agnes
Grosse Stephanie
Poirot Laurent
Scharenberg Andrew
Smith Julianne
SCHIFFER-MANNIOUI Cécile
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/892,805 external-priority patent/US11603539B2/en
Application filed by Cellectis filed Critical Cellectis
Publication of MX2015015638A publication Critical patent/MX2015015638A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con métodos para desarrollar células T diseñadas para inmunoterapia y más específicamente a métodos para modificar células T al inactivarse en genes de punto de control inmune, de preferencia al menos dos seleccionados de diferentes rutas para incrementar la actividad inmune de las células T. este método implica el uso de endonucleasas específicas de corte raro, en particular TALE-nucleasas (endonucleasas efectoras de TAL) y polinucleótidos que codifican tales polipéptidos para dirigir de forma precisa una selección de genes clave en células T, las cuales se encuentran disponibles a partir de donadores o del cultivo de células primarias. La invención abre la forma para estrategias de inmunoterapia adoptiva altamente eficientes para tratar cáncer e infecciones virales.
MX2015015638A 2013-05-13 2014-05-13 Metodos para diseñar celulas t altamente activas para inmunoterapia. MX2015015638A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/892,805 US11603539B2 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
PCT/US2013/040766 WO2013176916A1 (en) 2012-05-25 2013-05-13 Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
PCT/US2013/040755 WO2013176915A1 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US201361907858P 2013-11-22 2013-11-22
PCT/IB2014/061412 WO2014184744A1 (en) 2013-05-13 2014-05-13 Methods for engineering highly active t cell for immunotherapy

Publications (1)

Publication Number Publication Date
MX2015015638A true MX2015015638A (es) 2016-10-28

Family

ID=51897834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015638A MX2015015638A (es) 2013-05-13 2014-05-13 Metodos para diseñar celulas t altamente activas para inmunoterapia.

Country Status (9)

Country Link
EP (1) EP2997133B1 (es)
JP (1) JP2016524464A (es)
KR (1) KR102220382B1 (es)
CN (1) CN105378067A (es)
AU (1) AU2014266833B2 (es)
CA (1) CA2912375C (es)
MX (1) MX2015015638A (es)
RU (1) RU2725542C2 (es)
WO (1) WO2014184744A1 (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
SG11201601283PA (en) * 2013-08-22 2016-03-30 Queensland Inst Med Res Immunoreceptor modulation for treating cancer and viral infections
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP3808410A1 (en) * 2013-12-20 2021-04-21 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015155341A1 (en) * 2014-04-11 2015-10-15 Cellectis Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
JP2017513485A (ja) * 2014-04-18 2017-06-01 エディタス・メディシン，インコーポレイテッド がん免疫療法のためのｃｒｉｓｐｒ−ｃａｓ関連方法、組成物および構成要素
AU2015274242A1 (en) * 2014-06-10 2016-12-22 Monash University Method of producing leukocytes using PTPN2 inhibition for adoptive cell transfer
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
AU2015339744B2 (en) 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
GB201421096D0 (en) * 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
AU2016212162A1 (en) 2015-01-26 2017-07-13 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
CN115537396A (zh) * 2015-03-27 2022-12-30 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
CN107980046B (zh) 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
US10968426B2 (en) 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
EP3303586A1 (en) * 2015-05-29 2018-04-11 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
AU2016285859A1 (en) 2015-06-29 2018-02-15 The Johns Hopkins University Immune checkpoint chimeric antigen receptors therapy
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
CA2993431A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Nuclease based knockouts of immunological checkpoint genes in immune cells
CN108495641A (zh) * 2015-08-11 2018-09-04 塞勒克提斯公司 用于靶向cd38抗原和用于cd38基因失活的工程化的用于免疫疗法的细胞
WO2017040945A1 (en) 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
IL310721A (en) 2015-10-23 2024-04-01 Harvard College Nucleobase editors and their uses
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US11648268B2 (en) 2015-12-09 2023-05-16 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
SG11201807820PA (en) * 2016-03-11 2018-10-30 Bluebird Bio Inc Genome edited immune effector cells
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2017191504A1 (en) * 2016-05-03 2017-11-09 Oslo University Hospital Hf Validation of therapeutic t-cells
RU2745563C2 (ru) * 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102455249B1 (ko) * 2016-08-24 2022-10-17 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
JP2019528699A (ja) 2016-08-30 2019-10-17 メモリアル スローン ケタリング キャンサー センター ウイルスおよびその他の感染を処置するための免疫細胞組成物および使用の方法
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
IL265045B2 (en) 2016-09-08 2023-09-01 Bluebird Bio Inc Variants of endonuclease pd-1, compositions and methods of use
CN109715199A (zh) 2016-09-14 2019-05-03 詹森生物科技公司 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
CA3041831A1 (en) * 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of making genetically modified cells
WO2018080541A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN107760680B (zh) * 2016-12-28 2020-09-22 北京微旋基因技术有限公司 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
CN110914426A (zh) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 包含核酸可编程dna结合蛋白的核碱基编辑器
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
PE20191847A1 (es) 2017-06-02 2019-12-31 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
AU2018292181A1 (en) 2017-06-30 2020-01-23 Cellectis Cellular immunotherapy for repetitive administration
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
AU2018304173A1 (en) 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111511388A (zh) 2017-09-21 2020-08-07 博德研究所 用于靶向核酸编辑的系统、方法和组合物
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
JP2021502330A (ja) * 2017-10-20 2021-01-28 フレッド ハッチンソン キャンサー リサーチ センター Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法
CN109731012A (zh) * 2017-10-30 2019-05-10 邹兆中 提高生物免疫治疗有效物质活性的方法
CN111295189B (zh) 2017-11-01 2023-09-15 艾洛基治疗公司 修饰的胱天蛋白酶-9多肽及其使用方法
US20210363260A1 (en) 2017-11-13 2021-11-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
TW201936633A (zh) 2018-02-01 2019-09-16 美商輝瑞大藥廠 標靶至cd70的嵌合抗原受體
AU2019215075A1 (en) 2018-02-01 2020-08-20 Pfizer Inc. Antibodies specific for CD70 and their uses
CN112534044A (zh) * 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
EP3765608A4 (en) * 2018-03-15 2022-01-12 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
US20200208177A1 (en) * 2018-04-18 2020-07-02 Ligandal, Inc. Methods and compositions for genome editing
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN112218882A (zh) 2018-04-27 2021-01-12 西雅图儿童医院（Dba西雅图儿童研究所） Foxp3在经编辑的cd34+细胞中的表达
CN112368003A (zh) 2018-04-27 2021-02-12 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020113029A2 (en) * 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
CN113748126A (zh) * 2018-11-30 2021-12-03 因提玛生物科学公司 鉴定免疫调节基因的方法
EP3887507A1 (en) 2018-11-30 2021-10-06 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
CN113412117A (zh) 2018-12-12 2021-09-17 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041486A1 (en) 2019-08-27 2021-03-04 Janssen Biotech, Inc. Chimeric antigen receptor system and uses thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
EP4081537A1 (en) 2019-12-23 2022-11-02 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
AU2021232141A1 (en) 2020-03-03 2022-09-22 Janssen Biotech, Inc. ꝩδ T cells and uses thereof
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4176261A1 (en) 2020-07-03 2023-05-10 Cellectis S.A. Method for determining potency of chimeric antigen receptor expressing immune cells
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
EP4185616A1 (en) 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
CN116390746A (zh) 2020-07-31 2023-07-04 塞勒克提斯公司 双car-t细胞
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
TW202305118A (zh) 2021-03-23 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球之ｃｉｓｈ基因編輯及其在免疫療法中之用途
EP4330288A1 (en) 2021-04-30 2024-03-06 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
JP2024519041A (ja) 2021-05-21 2024-05-08 セレクティス ソシエテ アノニム 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
CA3226947A1 (en) 2021-08-03 2023-02-09 Muhammad YASSIN Engineered tcr complex and methods of using same
CN114480407B (zh) * 2021-12-07 2023-10-20 南京安吉生物科技有限公司 秀丽隐杆线虫基因组中clec126基因及其应用
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024078570A1 (en) * 2022-10-12 2024-04-18 Peking University Modified immune cells and uses thereof
WO2024094775A1 (en) 2022-11-03 2024-05-10 Cellectis S.A. Enhancing efficacy and safety of t-cell-mediated immunotherapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
JP4753119B2 (ja) 2003-03-14 2011-08-24 セレクティス ソシエテ アノニム 大量処理の生体外エレクトロポレーション法
US8409861B2 (en) * 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
AU2006224248B2 (en) 2005-03-15 2011-01-06 Cellectis I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2815512A1 (en) 2010-10-27 2012-05-03 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
WO2012138939A1 (en) 2011-04-05 2012-10-11 Philippe Duchateau New tale-protein scaffolds and uses thereof
US9540623B2 (en) 2011-07-08 2017-01-10 Cellectis Method for increasing the efficiency of double-strand-break induced mutagenesis
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof

Also Published As

Publication number Publication date
RU2015153241A3 (es) 2018-03-01
CA2912375C (en) 2023-03-14
RU2015153241A (ru) 2017-06-21
RU2725542C2 (ru) 2020-07-02
CA2912375A1 (en) 2014-11-20
KR20160030103A (ko) 2016-03-16
EP2997133B1 (en) 2023-08-23
JP2016524464A (ja) 2016-08-18
AU2014266833B2 (en) 2020-07-02
EP2997133C0 (en) 2023-08-23
WO2014184744A1 (en) 2014-11-20
AU2014266833A1 (en) 2015-12-24
KR102220382B1 (ko) 2021-02-25
BR112015028483A2 (pt) 2017-09-19
EP2997133A1 (en) 2016-03-23
CN105378067A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
MX2015015638A (es) Metodos para diseñar celulas t altamente activas para inmunoterapia.
MX2015015639A (es) Métodos para manipular células t alogénicas, altamente activas para inmunoterapia.
IN2014DN10991A (es)
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2022009512A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
EP3491134A4 (en) PLURIPOTENT HUMAN INDUCED STEM CELLS FOR HIGH-PERFORMANCE GENETIC ENGINEERING
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
PH12017500441A1 (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
GB2550745A (en) Crispr hybrid DNA/RNA Polynucleotides and methods of use
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
MY176746A (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
NZ739133A (en) Cellular targeted active ingredient delivery system
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
MX346160B (es) Peptidos que tienen actividad de inhibicion de infecciones de virus respiratorios, uso de los mismos y metodos de preparacion de los mismos.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MY184126A (en) Transposon system, kit comprising the same, and uses thereof
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
WO2013075105A3 (en) Tcl1 peptides for immunotherapy
WO2019012162A3 (en) GENOMIC EDITING METHOD IN HOST CELL
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.

Legal Events

Date Code Title Description
FG Grant or registration